From: Risk factors of prolonged ventilation after thymectomy in thymoma myasthenia gravis patients
Parameter | Group 1 (n = 74) | Group 2 (n = 38) | Z/χ2 | P-value |
---|---|---|---|---|
Age(years), M (p25, p75) | 51 (45,60) | 52 (40,67) | − 0.151 | 0.880 |
Male, n (%) | 27 (36.5) | 23 (60.5) | 5.871 | 0.015 |
BMI(kg/m2), M (p25, p75) | 24.2 (20.8,26.7) | 24.3 (21.8,26.2) | − 0.172 | 0.863 |
Smoking, n (%) | 9 (12.2) | 13 (34.2) | 7.733 | 0.005 |
VC(L), M (p25, p75) | 3.18 (2.64,3.84) | 3.03 (2.36,3.82) | − 1.000 | 0.317 |
Complications, n (%) | ||||
Cardiovascular disease | 6 (8.1) | 2 (5.3) | 0.028 | 0.868 |
Hypertension | 14 (18.9) | 8 (21.1) | 0.072 | 0.788 |
Pulmonary disease | 7 (9.5) | 2 (5.3) | 0.165 | 0.684 |
Osserman classification, n (%) | ||||
I + IIa | 50 (67.6) | 13 (34.2) | 11.352 | 0.001 |
IIb + III + IV | 24 (32.4) | 25 (65.8) | ||
Basic dose of pyridostigmine(mg/day), M (p25, p75) | 0 (0.180) | 180 (0,180) | − 1.906 | 0.057 |
Duration of the disease(day), M (p25, p75) | 60 (30.190) | 90 (30.225) | − 0.127 | 0.899 |
Size of thymomas (cm), M (p25, p75) | 4 (3.6) | 5 (3.8) | − 1.291 | 0.197 |